Upadacitinib hopes drug will reduce reliance on Humira.
New drug will be sold at around 30% discount to rivals.
AbbVie’s hepatitis C drug granted early access in UK
Trial backs patient-friendly regime in tough to treat strain.
Veliparib fails in two phase 3 trials.
Partner Incyte also hit after shock rejection.